Ionis director sells shares amid active regulatory and analyst developments
Joseph Loscalzo, a member of Ionis Pharmaceuticals' board, sold 1,032 shares in early March 2026 for roughly $82,832 and simultaneously exercised options to acquire the same number of shares at $38.06. The transactions coincide with a flurry of regulatory and clinical activity at the biotech, including an FDA acceptance of a supplemental NDA for ol…